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Background: Mobile health interventions provide significant strategies for improving access to health services, offering a
potential solution to reduce the mental health treatment gap. Economic evaluation of this intervention is needed to help inform
local mental health policy and program development.
Objective: This paper presents the protocol for an economic evaluation conducted alongside 2 randomized controlled trials
(RCTs) to evaluate the cost-effectiveness of a psychological intervention delivered through a technological platform (CONEMO)
to treat depressive symptoms in people with diabetes, hypertension, or both.
Methods: The economic evaluation uses a within-trial analysis to evaluate the incremental costs and health outcomes of
CONEMO plus enhanced usual care in comparison with enhanced usual care from public health care system and societal
perspectives. Participants are patients of the public health care services for hypertension, diabetes, or both conditions in São
Paulo, Brazil (n=880) and Lima, Peru (n=432). Clinical effectiveness will be measured by reduction in depressive symptoms and
gains in health-related quality of life. We will conduct cost-effectiveness and cost-utility analyses, providing estimates of the cost
per at least 50% reduction in 9-item Patient Health Questionnaire scores, and cost per quality-adjusted life year gained. The
measurement of clinical effectiveness and resource use will take place over baseline, 3-month follow-up, and 6-month follow-up
in the intervention and control groups. We will use a mixed costing methodology (ie, a combination of top–down and bottom–up
approaches) considering 4 cost categories: intervention (CONEMO related) costs, health care costs, patient and family costs, and
productivity costs. We will collect unit costs from the RCTs and national administrative databases. The multinational economic
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evaluations will be fully split analyses with a multicountry costing approach. We will calculate incremental cost-effectiveness
ratios and present 95% CIs from nonparametric bootstrapping (1000 replicates). We will perform deterministic and probabilistic
sensitivity analyses. Finally, we will present cost-effectiveness acceptability curves to compare a range of possible cost-effectiveness
thresholds.
Results: The economic evaluation project had its project charter in June 2018 and is expected to be completed in September
2021. The final results will be available in the second half of 2021.
Conclusions: We expect to assess whether CONEMO plus enhanced usual care is a cost-effective strategy to improve depressive
symptoms in this population compared with enhanced usual care. This study will contribute to the evidence base for health
managers and policy makers in allocating additional resources for mental health initiatives. It also will provide a basis for further
research on how this emerging technology and enhanced usual care can improve mental health and well-being in low- and
middle-income countries.
Trial Registration: ClinicalTrials.gov NCT12345678 (Brazil) and NCT03026426 (Peru);
https://clinicaltrials.gov/ct2/show/NCT02846662 and https://clinicaltrials.gov/ct2/show/NCT03026426
International Registered Report Identifier (IRRID): DERR1-10.2196/26164
(JMIR Res Protoc 2021;10(10):e26164) doi: 10.2196/26164
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Introduction
Globally, depression affects more than 264 million people each
year, with a high prevalence in Brazil and Peru (5.8% and 4.8%,
respectively). In Brazil, depressive disorders are ranked as the
fourth leading cause of years lived with disability, and thirteenth
for causing disability-adjusted life years [1]. In Peru, depressive
disorders account for 37% of the years lived with disability
attributed to mental health conditions and are responsible for
almost 46,000 disability-adjusted life years [2].
Chronic diseases such as hypertension and diabetes can be
exacerbated by depression, which is often undiagnosed and thus
remains untreated [3,4]. This can lead reduced quality of life,
increased physical health complications, and eventually a rise
in treatment costs for both the individual and the health economy
[4].
In low- and middle-income countries (LMICs) access to mental
health care remains extremely limited and unequal, with those
living in low-resource areas facing greater difficulties in
accessing mental health care [5,6]. This is due to limited
resource availability and a lack of trained health personnel. For
instance, in Brazil there are only 4.48 specialists per 100,000
inhabitants. A similar scenario is observed in Peru, with 2.06
psychiatrists and 6 psychiatric nurses per 100,000 people [7].
Most Brazilians and Peruvians with clinically relevant levels
of depressive symptoms currently do not receive any treatment.
There is thus a clear need to address the mental health treatment
gap within these settings.
Mobile health (mHealth) interventions offer potentially scalable
and affordable solutions to reduce the treatment gap in mental
health care (eg, depression). Studies on the effectiveness of
mHealth intervention in this regard have shown promising
results [8-11].
The Latin America Treatment and Innovation Network in Mental
Health (LATIN-MH), 1 of 5 hubs funded by the National
Institute of Mental Health (NIMH), conducted 2 randomized
controlled trials (RCTs) evaluating the effectiveness of a
low-intensity behavioral activation intervention for depression
(CONEMO). These aimed to reduce symptoms of depression
among individuals with hypertension, diabetes, or both
conditions attending public health care facilities in São Paulo,
Brazil, and Lima, Peru [12].
The acronym CONEMO is derived from the terms “Control”
and “Emotional” (meaning: emotional control). The intervention
is delivered via a smartphone app, and minimally supported by
a nurse/nurse assistant (NA). The app consists of 18 brief
mini-sessions, delivered automatically over a 6-week period,
with 3 mini-sessions per week. Each session requires less than
10 minutes to complete [12]. The CONEMO intervention seeks
to expand access to mental health care while using the available
health services in Brazil and Peru [13].
Although efforts have been made to ensure the effectiveness,
feasibility, and affordability of similar interventions, the success
and impact are primarily determined by regional differences in
cost structures and the burden of chronic diseases [14]. Cost
data provide essential information for financial planning and
enable decisions to be made regarding implementation
feasibility. This cost analysis may provide a critical contribution
to the planning and prioritization of interventions to address the
large and growing burden of depression in LMICs.
Although there is an increase in economic evaluations of
mHealth interventions, evaluations of these interventions in
LMICs remain limited [15]. This paper describes a protocol for
an economic evaluation to be conducted as part of 2 RCTs
evaluating the cost-effectiveness of CONEMO, an mHealth
intervention to treat symptoms of depression in people with
diabetes or hypertension or both in Brazil and Peru.
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The economic evaluation will follow the Methodological
Guidelines for Economic Evaluation Studies of Health
Technologies [16] and will be reported according to the
Consolidated Health Economic Evaluation Reporting Standards
(CHEERS) checklist [17]. The multinational economic
evaluations will be fully split analyses (incorporating estimates
of both resource use and clinical effectiveness from the same
group of patients from individual countries) with a multicountry
costing approach (applying unit cost estimates from individual
countries to account for resource use in each of those countries)
[18]. The within-trial analyses will be conducted using data
from the randomized control trials NCT02846662 and
NCT03026426, and secondary data on health service costs
extracted from governmental public databases. This protocol
outlines the methods for a cost-effectiveness analysis and
cost-utility analysis alongside the RCTs conducted in Brazil
and Peru, respectively.
The proposed economic evaluations will be conducted from
both the public health care system perspective (including only
health care system costs) and the societal perspective (including
health care system costs plus patient and productivity costs).
Study Population
All participants in the RCT will be included in the economic
evaluations. Participants include patients of the public health
care system in Brazil or Peru. Inclusion criteria were adults (age
≥21 years), able to read the screen of a smartphone, receiving
treatment for hypertension, diabetes, or both (self-report
validated with clinical records), and experiencing symptoms of
depression. Symptoms of depression were defined as obtaining
a score of 10 or more on the 9-item Patient Health Questionnaire
(PHQ-9) [19]. Participants were recruited from 20 primary care
units in São Paulo, Brazil, and from 4 primary care centers and
3 outpatient clinics in Lima, Peru.
Setting and Location
The Brazilian health care system is made up of 2 subsectors:
the National Health System (Sistema Único de Saúde [SUS]),
which is universal and free for everyone, and private health
insurance, which covers approximately 25% of the population.
Peru has a decentralized health care system administered by 5
providers: the Ministry of Health (MINSA), which provides
health services for 60% of the population; Social Security
(EsSalud), which covers 30% of the population; and the Armed
Forces (Fuerzas Armadas Españolas [FFAA]), Policía Nacional
del Perú (PNP), and private sector, which together provide
services to the remaining 10% of the population.
Both Brazilian and Peruvian health care systems have been
implementing several reforms over the last 2 decades. As a
result, health service networks in these countries are segmented
into primary, secondary, and tertiary care levels [6,20]. Patients
with diabetes and hypertension are typically seen within primary
care in Brazil (primary care units) and within either primary
(primary care centers) or secondary care units (hospital
outpatient clinics) in Peru.
The trials have been conducted in primary care settings (20
public primary care centers of the SUS) in Sao Paulo, Brazil,
and in 4 primary care centers in EsSalud and 3 outpatient clinics
in MINSA in Lima, Peru [21].
Comparators
In the Brazilian and Peruvian health care systems, there is no
screening policy for mental health in primary care units, where
the focus is on physical health. Mental health care is available
within specialized primary and secondary care services in both
countries. The usual care in the primary care setting integrates
practices of health promotion and clinical practice, which do
not include the use of depression screening instruments.
The economic evaluations will compare CONEMO plus
enhanced usual care with only enhanced usual care.
CONEMO Plus Enhanced Usual Care
The intervention group received CONEMO plus enhanced usual
care. CONEMO is a low-intensity mHealth intervention aimed
at reducing symptoms of depression. It is delivered via a
smartphone app, and is minimally supported by a nurse/NA.
The CONEMO app delivers 18 brief, automated mini-sessions
over a 6-week period, with 3 mini-sessions per week. Each
session is completed in less than 10 minutes.
The app content is based on behavioral activation, an
evidence-based psychological approach to treat depression.
Processed data on app usage were collected automatically and
reviewed in real-time by nurses/NAs through a dashboard
installed on tablets.
Nurses/NAs met with participants for an initial face-to-face
meeting, where participants received a smartphone with the app
preinstalled and completed a tutorial on its use. Nurses/NAs
made 2 mandatory phone calls to all CONEMO participants at
the beginning of the program to troubleshoot any difficulties
and enhance motivation for the use of CONEMO. Additional
calls were prompted through notifications sent to nurses/NAs
when the CONEMO automated system detected nonadherence.
Patients could request technical help through the help button
on the app. Nurses/NAs received training and were supervised
weekly by psychologists through face-to-face meetings or via
telephone.
Enhanced Usual Care
The control group received the usual care plus the following
procedures:
• Participants were screened using the PHQ-9 at baseline and
at 3- and 6-month follow-ups.
• Those with a score of 10 or more on the PHQ-9 were
advised to seek appropriate mental health care.
• Those presenting with suicide risk were referred to
specialized mental health services, by either a health
professional (in Sao Paulo and Lima) or the research team
(in Lima). In Lima, relatives or health care professionals
were also informed depending on risk severity.
• All participants received at least one call after screening at
inclusion, and at 3- and 6-month follow-up from the
research team to assess if they had sought specialized mental
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health care. Those with higher risk or who did not seek care
received additional phone calls.
Time Horizon and Discount Rate
Time horizon analyses will use the study follow-up period: 3
and 6 months after the inclusion of participants in the study in
order to understand its permanence effect. We truncated time
horizons to the length of follow-up in the RCTs because the
long-term health outcomes remain unclear and are not expected
to last beyond 6 months.
Following the recommendations of the Methodological
Guidelines for Economic Evaluation Studies of Health
Technologies [16], we will not apply the standard discount rate
of 5% on costs and benefits, because of the short (<1 year) time
horizons.
Choice of Health Outcomes and Measurement of
Effectiveness
Table 1 summarizes the health outcome measures and time of
collection for the outcomes that will be used in the economic
evaluations.
Two health outcomes will be measured: reduction in symptoms
of depression and health-related quality of life. First, the primary
outcome of effectiveness for the cost-effectiveness analysis will
be the proportion of patients with at least 50% reduction in
PHQ-9 scores. This indicator has been used in many depression
trials and is considered a robust way of symptom improvement
[22].
Second, the EuroQol 5-dimensional questionnaire, 3-level
version (EQ-5D-3L) will be used to measure health-related
quality of life and provide utilities for estimation of
quality-adjusted life years (QALYs). The EQ-5D-3L is a generic
preference-based measure used in many clinical trials for a wide
range of health conditions and treatments [23].
The measurement of clinical effectiveness will take place over
3 periods: baseline, 3-month follow-up, and 6-month follow-up.
Both countries used the same measures (PHQ-9 and EQ-5D-3L).
Table 1. Summary of health outcomes measured.
Source of dataTiming of collectionMeasuresHealth outcomes
Trials’ patient-reported outcomesBaseline, 3-month follow-up, and 6-month follow-upPHQ-9aDepressive symptoms
Trials’ patient-reported outcomesBaseline, 3-month follow-up, and 6-month follow-upEQ-5D-3LbQuality of life
aPHQ-9: 9-item Patient Health Questionnaire.
bEQ-5D-3L: EuroQol 5-dimensional questionnaire, 3-level version.
Estimating Resources and Costs
The cost estimation will involve 3 stages: (1) identification of
the costing items used to provide a particular service, (2)
measurement of the resources used, (3) application of monetary
value for each cost item, and calculation of the unit cost of a
particular service [24].
The measurement of the resources will take place over 3 periods,
baseline, 3-month follow-up, and 6-month follow-up, in the
intervention and control groups. These are the same periods
used to assess clinical effectiveness in the RCTs.
The measurement of resource use will be based on the group
of patients from each country. The costing approach will apply
unit cost estimates from Brazil and Peru to account for resource
use in each of those countries.
Costs will be applied to the resources based on the unit costs
or price weights most recently published in the respective
official government databases (Department of Informatics of
the National Health System, Departamento de Informática do
Sistema Único de Saúde [DATASUS] in Brazil; and the Integral
Health Insurance/Seguro Integral de Salud [SIS] in Peru). Other
resource use not recorded in DATASUS or SIS will be based
on LATIN-MH databases. These costs will be obtained in
Brazilian reals (R$) and Peruvian sols (S$), as per rates in 2017.
All costs will be adjusted for inflation using the Brazilian and
Peruvian consumer price indexes for the current reference year
(2021) and will be converted into international dollars (INT$)
using the 2021 purchasing power parity (PPP) conversion factors
for Brazil and Peru.
We will use a mixed costing methodology (ie, a combination
of top–down and bottom–up approaches) considering 4 cost
categories: intervention (CONEMO related) costs, health care
costs, patient and family costs, and productivity costs. Table 2
presents an overview of resource use and cost measures that
will be used in the economic evaluations. These include costs
hypothesized to differ between CONEMO plus enhanced usual
care (the intervention group) and enhanced usual care (the
control group).
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Table 2. Summary of cost categories measured.
Source of dataUnit costCost category and unit
Intervention (CONEMOa) costs
LATIN-MHa databasesCost/hourHour of supervisionStaff involved in supervision
LATIN-MH databasesCost/hourHour of a research assistantStaff involved in training
LATIN-MH databasesCost/tripNumber of tripsTransport
LATIN-MH databasesCost/monthMaintenance chargeDashboard and app maintenance




CEIb and ISSMcCost/visitNumber of visitsPsychiatrist visits
CEI and ISSMCost/visitNumber of visitsFamily physician visits
CEI and ISSMCost/visitNumber of visitsPsychologist visits
CEI, ISSM, and SAEsdCost/visitNumber of visitsEmergency room visits
CEI, ISSM, and SAEsCost/hospital admissionNumber of hospital admissionsHospital admissions
CEI and ISSMCost/doseNumber of dosesMedicines
Patient and family costs
Average cost for public transportCost/tripNumber of tripsTransport
Average market priceCost/monthMonthly packageInternet
Productivity costs
Average hourly wageCost/hourNumber of daysDays of work lost
aCONEMO: control emotional (emotional control intervention).
bLATIN-MH: Latin America Treatment and Innovation Network in Mental Health.
cCEI: Cost-Effectiveness Instrument.
dMental Health Instrument.
eSAE: Serious Adverse Events Report.
Intervention Costs
Intervention costs include the value of the staff time and
transport involved in either supervision or training of the primary
care workers that will use CONEMO.
We will assume that the intervention (CONEMO) is operational,
and so start-up costs, such as design and development of
CONEMO, will be excluded. Therefore, we will include only
costs for maintenance of the dashboard and app, internet package
costs, and expenditures related to office supplies and
infrastructure.
All of the research-related costs associated with trial
administration, data collection, and outcome assessment of
RCTs will be excluded.
Health Care Costs
Health care costs will include direct medical costs: outpatient
visits, emergency room and hospital admissions, and medicines
prescribed during the study period.
Patient and Family Costs
Patient and family costs will include direct nonmedical costs,
such as transport for seeking health care and internet
expenditures. In São Paulo, we will assume that for each hospital
admission, there will be 2 public transport trips. For those aged
over 60, we will add a companion cost (according to Article 16
of the Brazilian Elderly Statute) [25]. In case of attendance at
the primary care centers, no transportation cost will be
calculated, as we are assuming participants will be attending a
local service. In Lima, we will consider the use of 2 public
transport trips for all participants. For participants aged over
60, considering the lack of specific regulations, we agreed on
including an additional 50% cost for caregiver transportation.
We assumed that the patients already own a smartphone and
included only the costs of internet access.
Productivity Costs
Productivity costs will include indirect costs related to lost days
of work due to morbidity and will be estimated according to
the human capital approach [26]. Productivity costs associated
with depressive symptoms will be calculated by multiplying
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the number of hours absent with an average hourly wage in
Brazil and Peru.
Policy Statement, Data Analysis, and Security
Responsibilities
The RCTs were approved by the Data and Safety Monitoring
Board (DSMB) of the NIMH, USA, and local ethics committees
in São Paulo and Lima.
Primary data (phase 1) were collected on ethical standards and
underwent internal and external audit by the DSMB. Secondary
data (phase 2) will follow the same guidelines for quality
purposes.
Informed consent was obtained from participants by the research
team at screening and baseline. Consent for this study was
obtained as part of the RCT procedures.
Study coordinators (DdS and PS) will carry out the collection
and analysis of secondary data from each country with the
support of the LATIN-MH Data Center team and a specialized
consultant under the supervision of the principal investigators
(PM and RA). Data sets will be anonymized by removing
personal identifiers (eg, name, phone number) to protect the
confidentiality of study participants.
Analytic Methods
Mean values of the estimated health outcomes and costs, as well
as mean differences between the comparator groups (CONEMO
plus enhanced usual care versus enhanced usual care) will be
reported. Incremental cost-effectiveness ratios (ICERs) will be
calculated as the arithmetic mean difference in cost between
CONEMO plus enhanced usual care and enhanced usual care,
divided by the arithmetic mean difference in effect. For the
cost-effectiveness analysis, the corresponding ICER will be
expressed as the incremental costs per at least 50% reduction
of PHQ-9 scores. In the cost-utility analysis, the ICER will be
expressed as the incremental costs per QALY gained. ICERs
will be generated by nonparametric bootstrapping methods using
random resamples for every 1000 pairs of outcomes and costs
for the intervention and comparator groups to derive 95% CIs
[27]. The distribution of mean incremental costs and outcomes
shown on cost-effectiveness will be conducted to test the
robustness of results.
Sensitivity Analyses
Deterministic and probabilistic sensitivity analyses will be
performed to determine the level of confidence around the
resulting ICERs. Several deterministic (1 way) sensitivity
analyses will be carried out by varying the key parameters (such
as quantity of resource use, unit cost of resource use, QALYs)
in the within-trial analyses. Results from deterministic sensitivity
analyses will be presented in a tornado diagram to compare the
relative importance of the parameters with the ICER. The results
from the probabilistic sensitivity analysis will also be presented
using cost-effectiveness acceptability curves [28]. This curve
indicates the probability that the CONEMO plus enhanced usual
care is cost-effective compared with enhanced usual care,
considering the thresholds range of $PPP3210-$PPP10,122 per
QALY gained for Brazil, and of $PPP1969-$PPP7747 per
QALY gained for Peru [29].
Statistical Software Use for Health Economic Analysis
Stata (StataCorp) version 15.0 or higher will be used for all
health economics analyses.
Results
Phase 1 of the project ran from September 2016 to April 2018
to assess the applicability of CONEMO. Phase 2 began in June
2018 and is expected to be completed in September 2021. The
economic evaluation of CONEMO will be conducted during
this phase. Results will be used to report the costs of CONEMO
to help plan the implementation of the intervention. The
evaluation will also calculate the cost-effectiveness of
CONEMO to improve symptoms of depression.
Discussion
Overview
Assessing the economic viability of the CONEMO intervention
based on its cost-effectiveness will enable us to ascertain the
feasibility of its implementation in primary and secondary care.
If shown to be financially viable, the intervention could help
bridge the treatment gap and increase access to mental health
care. If the ICER is favorable, there would be a strong case for
policymakers to support the scale-up of this intervention.
Implementing the CONEMO intervention would enable the
screening, identification, and treatment of depression in patients
with chronic diseases. The expected result is a reduction in
symptoms and likely an increase in self-care, adherence to
treatment, and quality of life. These outcomes could also result
in fewer complications and required resources, as well as
reduced health care costs. Using nursing staff to support patients
rather than specialized mental health professionals and
specialized services could also be an efficient use of human
resources, thereby saving costs in the longer term.
Economic evaluations are particularly important because they
can be used to guide decision makers or funders in determining
if the mHealth interventions improve health outcomes when
compared to other existing interventions [15]. They are also
important for analyzing whether the cost to adopt and maintain
the intervention in a health system is justified. One of the
barriers of mHealth implementation and scale-up is the financial
feasibility, yet few studies include or detail operational costs
of mobile communication, such as fees charged to end users
(patients).
Generalizability and Future Research
If found to be clinically effective and cost-effective, CONEMO
could be used in other populations with similar treatment gaps
[13]. Replication has been made possible by the standardized
materials used. The generalizability of results is likely high due
to the diverse in-country heterogeneous sample and its
implementation in 2 countries.
• Implications for health provision and use: We would seek
to collaborate with other services to develop further
evidence for implementation.
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• Implications for health policies: Despite some limitations,
this protocol will be used to measure the costs of mental
health services in 2 studies, generating data to support local
mental health policies, boost research in the country, and
support new studies.
Study Limitations
Health economic evaluation studies on mHealth interventions
have not been conducted in Brazil and Peru; while this is an
innovative research study, some limitations remain. These are
as follows:
• Cost-effectiveness analysis may be hampered by the scarcity
of economic and epidemiological data available and the
composition of the variables for each cost when found.
• Peruvian analysis will follow Brazilian guidelines due to
the lack of guidelines for health economic evaluation in
Peru.
• Some cost items will be based on other similar items, which
do not express the same precision level of a specialized
service sample collected on official cost indicator databases.
• Difficulty in including all indirect costs incurred from the
societal perspective due to insufficient information related
to the treatments under analysis.
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